What is Leerink Partnrs' Estimate for ITOS Q2 Earnings?

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Stock analysts at Leerink Partnrs issued their Q2 2025 EPS estimates for iTeos Therapeutics in a research report issued on Wednesday, May 14th. Leerink Partnrs analyst D. Graybosch expects that the company will earn ($0.62) per share for the quarter. Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for iTeos Therapeutics' current full-year earnings is ($3.49) per share. Leerink Partnrs also issued estimates for iTeos Therapeutics' Q3 2025 earnings at ($0.48) EPS, FY2026 earnings at ($1.19) EPS, FY2027 earnings at ($1.41) EPS and FY2028 earnings at ($1.94) EPS.

A number of other equities research analysts have also recently commented on the company. Raymond James set a $12.00 price target on iTeos Therapeutics in a research note on Wednesday, May 14th. HC Wainwright lowered shares of iTeos Therapeutics from a "buy" rating to a "neutral" rating in a research report on Wednesday, May 14th. Wells Fargo & Company reaffirmed an "overweight" rating and issued a $13.00 price target (down previously from $16.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Leerink Partners restated a "market perform" rating and issued a $9.00 target price (down previously from $47.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 14th. Finally, Piper Sandler restated an "overweight" rating and issued a $12.00 target price (down previously from $16.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 14th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $17.86.

iTeos Therapeutics Trading Down 1.5%

Shares of ITOS traded down $0.13 during midday trading on Monday, hitting $8.56. 611,821 shares of the company's stock traded hands, compared to its average volume of 569,146. iTeos Therapeutics has a 1 year low of $4.80 and a 1 year high of $18.13. The firm's fifty day moving average is $6.72 and its 200-day moving average is $7.40. The stock has a market capitalization of $327.63 million, a price-to-earnings ratio of -2.72 and a beta of 1.39.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last posted its earnings results on Monday, April 28th. The company reported ($0.80) EPS for the quarter, beating analysts' consensus estimates of ($0.94) by $0.14.

Hedge Funds Weigh In On iTeos Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Acadian Asset Management LLC raised its stake in shares of iTeos Therapeutics by 14.2% during the 1st quarter. Acadian Asset Management LLC now owns 536,787 shares of the company's stock valued at $3,203,000 after buying an additional 66,641 shares during the last quarter. Jane Street Group LLC raised its position in iTeos Therapeutics by 117.1% during the first quarter. Jane Street Group LLC now owns 21,438 shares of the company's stock valued at $128,000 after acquiring an additional 147,107 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of iTeos Therapeutics during the 1st quarter valued at approximately $67,000. BVF Inc. IL increased its holdings in shares of iTeos Therapeutics by 32.3% during the 1st quarter. BVF Inc. IL now owns 3,075,000 shares of the company's stock valued at $18,358,000 after purchasing an additional 750,000 shares in the last quarter. Finally, AQR Capital Management LLC increased its holdings in iTeos Therapeutics by 88.6% in the first quarter. AQR Capital Management LLC now owns 226,210 shares of the company's stock valued at $1,350,000 after buying an additional 106,260 shares in the last quarter. Hedge funds and other institutional investors own 97.16% of the company's stock.

Insiders Place Their Bets

In related news, major shareholder Ansbert Gadicke sold 1,031,931 shares of the firm's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the completion of the transaction, the insider now owns 3,452,797 shares of the company's stock, valued at $27,829,543.82. This trade represents a 23.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the firm's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total transaction of $5,079,339.46. Following the transaction, the insider now directly owns 2,108,594 shares of the company's stock, valued at approximately $16,995,267.64. This trade represents a 23.01% decrease in their position. The disclosure for this sale can be found here. 12.50% of the stock is currently owned by insiders.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.